LOS ANGELES, April 04, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Graña y Montero S.A.A. (“Graña y Montero” or the “Company”) (NYSE:GRAM) concerning possible violations of federal securities laws between July 24, 2013 and February 24, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the April 28, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Graña y Montero made false and/or misleading statements and/or failed to disclose: that the Company was aware that its Brazilian partner Odebrecht S.A. paid bribes to former Peruvian President Alejandro Toledo to win construction work on a road traveling from Peru to Brazil; and as a result, the Company's statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On February 24, 2017, Reuters published an article highlighting a report that Graña y Montero knew about $20 million in bribes paid to former Peruvian President Alejandro Toledo by its partner Odebrecht. When this information reached the public, shares of the Company fell in value.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/


Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 



